

Special Issue

Advances in the Molecular Biology and Pathology of Breast Cancer

Message from the Guest Editor

Breast cancer is one of the most prevalent malignancies worldwide. Comprehensive and multi-layered analysis has revealed the molecular and biologic heterogeneity of breast cancer with the recognition of distinct subtypes linked to different aetiological pathways.

These efforts have affirmed hormone receptor and HER2 signalling pathways as major biological drivers of breast cancer. Classification systems are evolving that integrate molecular and morphologic information, and complex genomic assays now form part of the diagnostic armamentarium that informs management decisions. More recently, molecular targets have emerged as promising therapeutic options, particularly in the advanced setting. Notwithstanding the tremendous advances made, treatment options remain limited for some subtypes of breast cancer for which the prognosis remains poor. This Special Issue will cover recent advances in the molecular biology and pathology of breast cancer that work towards improving the diagnosis, management and outcomes for patients with the disease.

Guest Editor

Prof. Dr. Grace Callagy

Discipline of Pathology, School of Medicine, Lambe Institute for Translational Research, University of Galway, H91 TK33 Galway, Ireland

Deadline for manuscript submissions

closed (23 August 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/191215

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)